# The HAM Infliximab Study

> **NCT00823641** · PHASE2 · TERMINATED · sponsor: **Imperial College London** · enrollment: 3 (actual)

## Conditions studied

- HTLV-I-associated Myelopathy

## Interventions

- **DRUG:** Infliximab

## Key facts

- **NCT ID:** NCT00823641
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-10
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Higher toxicity rate than observed in studies in Rheumatoid arthritis
- **Last updated:** 2013-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00823641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00823641, "The HAM Infliximab Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00823641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*